



Biofluid Collections in ADNI3

Summary as of February 8, 2019

The table below is a summary of Biofluids Received and processed to date by the ADNI Biomarker Core team as of February 8, 2019 from NEW ENROLLEES and ROLLOVER ADNI participants. The biofluids report also provides biofluids received from each diagnostic group (Cognitively Normal, MCI and AD ADNI3 participants). In order to assess the % of participants who provided CSF we show in the last column for New Enrollees, calculated as the number of participant CSF samples divided by the number of plasma samples provided during the BASELINE visit (Initial Visit). Approximately 75% (71.6 – 76.8%) of New Enrollees provided CSF whereas an average of 36.1% (33.9 – 44.7%) of Rollover participants provided CSF at their Initial Visit. Since one of the hallmark values of the ADNI study is characterizing the longitudinal trajectories of the biomarkers, all investigators making use of ADNI study data place very high value on all of these biofluid samples and feel that continued efforts to encourage collections of longitudinal samples are highly valuable and important to AD biomarker research. Almost every new study, including those we conduct for “core” AD biomarkers in the Biomarker Core and new candidate AD biomarkers, as well as those analyzed by investigators whose studies are approved by the ADNI/NIA-Research Allocation Review Committee, are making use of a combination of BASELINE plus LONGITUDINAL biofluid samples. None of this would be possible without the continued collections of these irreplaceable biofluid samples from study participants by our ADNI sites.

ADNI Biomarker Core team at UPENN

ADNI 3 Primary Biofluids Received by Total Patients Baseline/Initial Visit				
	CSF RECEIVED	PLASMA RECEIVED	SERUM RECEIVED	LP %
COGNITIVE NORMAL	261	439	439	59.45
MILD COGNITIVE IMPAIRMENT	97	196	196	49.49
DEMENTIA	35	63	64	55.56
TOTAL	393	698	699	56.3

ADNI 3 Primary Biofluids Received by Rollover Patients Initial Visit				
	CSF RECEIVED	PLASMA RECEIVED	SERUM RECEIVED	LP %
COGNITIVE NORMAL	66	185	185	35.68
MILD COGNITIVE IMPAIRMENT	39	115	115	33.91
DEMENTIA	17	38	39	44.74
TOTAL	122	338	339	36.09

ADNI 3 Primary Biofluids Received by New Enrollees Baseline				
	CSF RECEIVED	PLASMA RECEIVED	SERUM RECEIVED	LP %
COGNITIVE NORMAL	195	254	254	76.77
MILD COGNITIVE IMPAIRMENT	58	81	81	71.6
DEMENTIA	18	25	25	72
TOTAL	271	360	360	75.28

ADNI 3 Primary Biofluids Received by Patients Baseline + Longitudinal			
	CSF RECEIVED	PLASMA RECEIVED	SERUM RECEIVED
COGNITIVE NORMAL	262	483	483
MILD COGNITIVE IMPAIRMENT	100	258	259
DEMENTIA	35	81	82
TOTAL	397	822	824

ADNI 3 Primary Biofluids Received by Rollover Patients Baseline + Longitudinal			
	CSF RECEIVED	PLASMA RECEIVED	SERUM RECEIVED
COGNITIVE NORMAL	66	221	221
MILD COGNITIVE IMPAIRMENT	42	168	169
DEMENTIA	17	53	54
TOTAL	125	442	444

ADNI 3 Primary Biofluids Received by Received by New Enrollees Baseline + Longitudinal			
	CSF RECEIVED	PLASMA RECEIVED	SERUM RECEIVED
COGNITIVE NORMAL	196	262	262
MILD COGNITIVE IMPAIRMENT	58	90	90
DEMENTIA	18	28	28
TOTAL	272	380	380